KDM5D and neoplasm: The ChIP assay results further indicated that JARID1D knockdown increased H3K4me3 levels at the JunD promoter (Figure 7G), suggesting that JARID1D in tumor cells can directly demethylate and regulate JunD in osteoclasts, thus affecting bone metastasis in PCa.